^
Association details:
Biomarker:EGFR expression
Cancer:Non Small Cell Lung Cancer
Drug:gefitinib (EGFR inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: B - Late Trials
New
Title:

Molecular Predictors of Outcome With Gefitinib in a Phase III Placebo-Controlled Study in Advanced Non–Small-Cell Lung Cancer

Excerpt:
The survival benefit for patients with EGFR protein expression–positive tumors treated with gefitinib (HR, 0.77; 95% CI, 0.56 to 1.08; P = .126) was slightly greater than for the overall study population (Table 1), with no evidence of a survival benefit of gefitinib to patients with EGFR protein expression–negative tumors (HR, 1.57; 95% CI, 0.86 to 2.87; P = .140). EGFR protein expression–positive patients also seemed to achieve better response rates (8.2% v 1.5%) than EGFR protein expression–negative patients (Table 3).
DOI:
10.1200/JCO.2006.06.3958